Author

D. A. Zwijnenburg

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1

Frequent Co-Authors

J. Koster· 2 shared A. Chan· 1 shared A. Coffin· 1 shared A. Lakeman· 1 shared A. Patel· 1 shared A. Shillings· 1 shared A. Y. F. Li Yim· 1 shared C. E. Blunt· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Koster

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

An immature subset of neuroblastoma cells synthesizes retinoic acid and depends on this metabolite

T. van Groningen, C. U. Niklasson, A. Chan, N. Akogul, E. M. Westerhout, K. von Stedingk, M. Hamdi, L. J. Valentijn, S. Mohlin, P. Stroeken, N. E. Hasselt, F. Haneveld, A. Lakeman, D. A. Zwijnenburg, P. van Sluis, , J. van Nes

The paper identifies an immature neuroblastoma subset that synthesizes retinoic acid and is resistant to it, potentially contributing to therapy-resistant relapses.

bioRxiv · May 18, 2021 · PreprintCancer Biology

Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140

M. Ghiboub, J. Koster, P. D. Craggs, A. Y. F. Li Yim, A. Shillings, S. Hutchinson, R. P. Bingham, K. Gatfield, I. L. Hageman, G. Yao, H. P. O'Keefe, A. Coffin, A. Patel, L. A. Sloan, D. J. Mitchell, , W. J. de Jonge

This study identifies SP140 as a druggable epigenetic reader and therapeutic target for Crohn's disease by showing that its inhibition reduces inflammatory macrophage activation and cytokine expression.

bioRxiv · Aug 10, 2020Immunology